A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine (NCT06619509)
A Phase II, Single-arm, Open-label, Long-term Safety Rollover Trial of Oral Brigimadlin in Patients With Solid Tumours
🩺 Plain-English Summary (8th-Grade Level)
This study is open to adults with solid tumours who received at least 4 cycles of treatment with brigimadlin in a previous study. The goal of this study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a so-called MDM2 inhibitor that was being developed to treat cancer. All participants take brigimadlin as tablets once every 3 weeks at the study site. At study visits, doctors check participants' health and take note of any unwanted effects. At some study visits, doctors also check the size of the tumour and whether it has spread to other parts of the body. Participants are in the study as long as they benefit from treatment and can tolerate it.
Who can join: Review the eligibility criteria below.
Location: Precision NextGen Oncology — Beverly Hills, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (50 Sites)
Showing the first 25 of 50 sites.
- Precision NextGen Oncology — Beverly Hills, California
- Sarcoma Oncology Center — Santa Monica, California
- Yale Cancer Center — New Haven, Connecticut
- Mayo Clinic Cancer Center — Jacksonville, Florida
- Washington University School of Medicine — St Louis, Missouri
- Nebraska Cancer Specialists-Omaha-69066 — Omaha, Nebraska
- Northwell Health — Lake Success, New York
- West Cancer Center & Research Institute — Germantown, Tennessee
- Henry-Joyce Cancer Clinic — Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- Utah Cancer Specialists Cancer Center — Salt Lake City, Utah
- Fred Hutchinson Cancer Research Center — Seattle, Washington
- University of Wisconsin — Madison, Wisconsin
- Sanatorio Finochietto — CABA,
- Prince of Wales Hospital-Randwick-66496 — Randwick, New South Wales
- Princess Alexandra Hospital — Woolloongabba, Queensland
- Cliniques Universitaires Saint-Luc — Brussels,
- UZ Leuven — Leuven,
- Arthur J. E. Child Comprehensive Cancer Centre — Calgary, Alberta
- Princess Margaret Cancer Centre — Toronto, Ontario
- Sun Yat-Sen University Cancer Center — Guangzhou,
- University Hospital Olomouc — Olomouc,
- Copenhagen University Hospital, Rigshospitalet — København Ø,
- CTR Leon Berard — Lyon,
- CTR Eugène Marquis — Rennes,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumours
- Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours — New York, New York
- A Study of BI 3810944 in Patients With Advanced Cancer — Louisville, Kentucky
- A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors — Irvine, California
- A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors — Beverly Hills, California
- Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations — Anchorage, Alaska
Explore by condition: All Solid Tumours clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.